Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH).

Full DD Report for ANTH

You must become a subscriber to view this report.


Recent News from (NASDAQ: ANTH)

New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, Anthera Pharmaceuticals, and Alexandria Real Estate Equities - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global Medical REIT Inc. (NYSE:GMRE), DXP Enterprises, Inc. (NASDAQ:DXPE),...
Source: GlobeNewswire
Date: May, 04 2018 08:20
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph...
Source: SeekingAlpha
Date: April, 09 2018 13:39
Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight Medical Products, Eclipse Resources, and Aircastle with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Hancock Holding Company (NA...
Source: GlobeNewswire
Date: March, 19 2018 07:30
Anthera Fails Phase 3 Study, Time To Avoid
Recently, Anthera Pharmaceuticals ( ANTH ) reported results from its Phase 3 trial treating exocrine pancreatic insufficiency ((“EPI”)) due to cystic fibrosis. It noted that the Phase 3 study failed to meet the primary endpoint . This sent shares of Anthera trading lower for...
Source: SeekingAlpha
Date: March, 15 2018 13:54
U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018
The inflation data released today was underwhelming (bullish for stocks). Today was a small pullback day for U.S. equities after the recent rally from February lows but new highs are likely. Anthera Pharmaceuticals ( ANTH ) is trading at a market cap of just $11.3 million after the failur...
Source: SeekingAlpha
Date: March, 14 2018 14:21
3 Things In Biotech, March 13, 2018: Uncertainty Abounds!
Note: Subscribers to Avisol Capital Partners' Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biote...
Source: SeekingAlpha
Date: March, 14 2018 08:00
Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow
The following slide deck was published by Anthera Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 13 2018 13:17
Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA
Analysis of top Seeking Alpha coverage: Coherus Biosciences Today we will discuss Coherus Biosciences (CHRS), which surged last Friday after the company announced that it is set to resubmit its application for Neulasta biosimilar. The company also noted that it expects an approval for the...
Source: SeekingAlpha
Date: March, 13 2018 07:30
Midday Gainers / Losers (3/12/2018)
Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 12 2018 12:45
Premarket Losers as of 9:05 am (3/12/2018)
ANTH   -84%  on  terminating development of Sollpura after failed late-stage study. More news on: Anthera Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Savara Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 12 2018 09:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.080.0820.100.0885,512
2018-08-160.090.090.120.08268,902
2018-08-150.080.089310.09090.07693,995
2018-08-140.07750.0850.0890.075212,792
2018-08-130.08550.0750.0860.075128,471

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-27690,5522,871,62024.0475Cover
2018-06-2646,850124,90937.5073Short
2018-06-2534,34577,60544.2562Short
2018-06-2248,27284,35257.2269Short
2018-06-2124,66884,34529.2465Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ANTH.


About Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH)

Logo for Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH)

Not available

 

Contact Information

 

 

Current Management

  • Paul Truex / CEO
  • Christopher Lowe / CFO

Current Share Structure

  • Market Cap: $7,435,725 - 05/14/2018
  • Issue and Outstanding: 23,397,497 - 02/28/2018

 


Recent Filings from (NASDAQ: ANTH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 05 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ANTH)

Daily Technical Chart for (NASDAQ: ANTH)


Stay tuned for daily updates and more on (NASDAQ: ANTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ANTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ANTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ANTH and does not buy, sell, or trade any shares of ANTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/